Promoting Health through Vitamin D Therapeutics

Improving People's Lives by Treating and Preventing the Clinical Consequences of
Vitamin D Insufficiency and Secondary Hyperparathyroidism

  

Recent News:

FDA Approves New Drug Application for RAYALDEE® to Treat Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Stage 3-4 Chronic Kidney Disease
June 21, 2016

OPKO Announces Appointment of Douglass Laidlaw as Vice President of Medical Affairs
May 11, 2016

OPKO Announces Appointment of Thomas Nusbickel as Senior Vice President of
Pharmaceutical Marketing and Market Access
May 10, 2016
 
     
 

 

© 2016 OPKO Health Inc.- All rights reserved. | Privacy Policy | Terms Of Use